Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C E FORD

Showing results (41-50 of 59) with videos related to

Pageof 6
Sort By:
The Pharmacogenomics Journal|June 6, 2012
RYR3 gene polymorphisms and cardiovascular disease outcomes in the context of antihypertensive treatmentA I Lynch, M R Irvin, E Boerwinkle, et al.
Journal of Human Hypertension|January 22, 2016
The effects of genes implicated in cardiovascular disease on blood pressure response to treatment among treatment-naive hypertensive African Americans in the GenHAT studyA N Do, A I Lynch, S A Claas, et al.
Journal of Medicinal Chemistry|April 10, 1999
Structure-based design, synthesis, and biological evaluation of irreversible human rhinovirus 3C protease inhibitors. 3. Structure-activity studies of ketomethylene-containing peptidomimeticsP S Dragovich, T J Prins, R Zhou, et al.
Food and Chemical Toxicology : an International Journal Published for the British Industrial Biological Research Association|November 18, 2005
Effects of oral androstenedione on phospholipid fatty acids, ATP, caspase-3, prostaglandin E(2) and C-reactive protein in serum and livers of pregnant and non-pregnant female ratsP W Wiesenfeld, P P Sapienza, T J Flynn, et al.
Controlled Clinical Trials|February 13, 2001
Operational aspects of terminating the doxazosin arm of The Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)S L Pressel, B R Davis, J T Wright, et al.
Science (New York, N.Y.)|June 20, 1998
Molecular basis for interactions of G protein betagamma subunits with effectorsC E Ford, N P Skiba, H Bae, et al.
Journal of Medicinal Chemistry|December 20, 1996
Design, synthesis, and evaluation of nonpeptidic inhibitors of human rhinovirus 3C proteaseS E Webber, J Tikhe, S T Worland, et al.
Antimicrobial Agents and Chemotherapy|October 3, 1999
In vitro antiviral activity of AG7088, a potent inhibitor of human rhinovirus 3C proteaseA K Patick, S L Binford, M A Brothers, et al.
Bioorganic & Medicinal Chemistry Letters|August 28, 1999
Structure-based design of irreversible, tripeptidyl human rhinovirus 3C protease inhibitors containing N-methyl amino acidsP S Dragovich, S E Webber, T J Prins, et al.
Journal of Medicinal Chemistry|May 5, 2000
Substituted benzamide inhibitors of human rhinovirus 3C protease: structure-based design, synthesis, and biological evaluationS H Reich, T Johnson, M B Wallace, et al.
Pageof 6

Showing results (41-50 of 59) with videos related to

Sort By:
Pageof 6
The Pharmacogenomics Journal|June 6, 2012
RYR3 gene polymorphisms and cardiovascular disease outcomes in the context of antihypertensive treatmentA I Lynch, M R Irvin, E Boerwinkle, et al.
Journal of Human Hypertension|January 22, 2016
The effects of genes implicated in cardiovascular disease on blood pressure response to treatment among treatment-naive hypertensive African Americans in the GenHAT studyA N Do, A I Lynch, S A Claas, et al.
Journal of Medicinal Chemistry|April 10, 1999
Structure-based design, synthesis, and biological evaluation of irreversible human rhinovirus 3C protease inhibitors. 3. Structure-activity studies of ketomethylene-containing peptidomimeticsP S Dragovich, T J Prins, R Zhou, et al.
Food and Chemical Toxicology : an International Journal Published for the British Industrial Biological Research Association|November 18, 2005
Effects of oral androstenedione on phospholipid fatty acids, ATP, caspase-3, prostaglandin E(2) and C-reactive protein in serum and livers of pregnant and non-pregnant female ratsP W Wiesenfeld, P P Sapienza, T J Flynn, et al.
Controlled Clinical Trials|February 13, 2001
Operational aspects of terminating the doxazosin arm of The Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)S L Pressel, B R Davis, J T Wright, et al.
Science (New York, N.Y.)|June 20, 1998
Molecular basis for interactions of G protein betagamma subunits with effectorsC E Ford, N P Skiba, H Bae, et al.
Journal of Medicinal Chemistry|December 20, 1996
Design, synthesis, and evaluation of nonpeptidic inhibitors of human rhinovirus 3C proteaseS E Webber, J Tikhe, S T Worland, et al.
Antimicrobial Agents and Chemotherapy|October 3, 1999
In vitro antiviral activity of AG7088, a potent inhibitor of human rhinovirus 3C proteaseA K Patick, S L Binford, M A Brothers, et al.
Bioorganic & Medicinal Chemistry Letters|August 28, 1999
Structure-based design of irreversible, tripeptidyl human rhinovirus 3C protease inhibitors containing N-methyl amino acidsP S Dragovich, S E Webber, T J Prins, et al.
Journal of Medicinal Chemistry|May 5, 2000
Substituted benzamide inhibitors of human rhinovirus 3C protease: structure-based design, synthesis, and biological evaluationS H Reich, T Johnson, M B Wallace, et al.
Pageof 6